Dosing chart / Healing & recovery
BPC-157 vs KPV
Dose, schedule, route and approval status side by side.
Reference only, not medical advice. Doses marked FDA-approved come from the US prescribing label. Doses marked Not approved are ranges reported from small studies or community use and have not been established as safe or effective in humans. Check anything here with a licensed clinician before acting on it. Read the full disclaimer.
| BPC-157 | KPV | |
|---|---|---|
| Status | Not approved | Not approved |
| Also known as | body protection compound | alpha-MSH fragment |
| Typical dose | 250–500 mcg | 200–500 mcg |
| How often | Daily | Daily |
| Schedule | Daily, often split into two doses. | Once daily. |
| Daily equivalent | 250–500 mcg/day | 200–500 mcg/day |
| Route | Subcutaneous or oral | Subcutaneous or oral |
| Duration | 4–8 weeks reported | 4–8 weeks reported |
| Notes | Nearly all evidence is from animal studies. The FDA has flagged it as a substance that poses safety risks in compounding. | Anti-inflammatory tripeptide studied in cells and animals only. |
This page sets the two chart entries next to each other. It does not say which is better or whether either is right for you. Read member experiences on the BPC-157 and KPV pages.
Advertisement